A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age

@inproceedings{PavaRuz2013ARC,
  title={A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age},
  author={Noris Pav{\'i}a-Ruz and Miguel Angel Rodriguez Weber and Yu Lung Lau and E Anthony S Nelson and Angkool Kerdpanich and Li-Min Huang and Peter E Silas and Paul Y Qaqundah and Mark M Blatter and Robert J Jeanfreau and Paul Lei and Varsha K. Jain and Mohamed El Idrissi and Yang Feng and Bruce L. Innis and Mathieu Peeters and Jeanne-Marie Devaster},
  booktitle={Human vaccines & immunotherapeutics},
  year={2013}
}
The trivalent inactivated influenza vaccine Fluarix™ is licensed in the US for adults and children from 3 years old. This randomized observer-blind study (NCT00764790) evaluated Fluarix™ at two doses; 0.25 ml (Flu-25) and 0.5 ml (Flu-50) in children aged 6-35 months. The primary objective was to demonstrate immunogenic non-inferiority vs. a control vaccine… CONTINUE READING